Related Experiment Video
Updated: Jun 7, 2025
Identification and Quantification of Deranged Metabolites in Critically Ill Patients Using NMR-Based Metabolomics
Published on: November 29, 2024
Analysis of variable metabolites in preterm infants with bronchopulmonary dysplasia: a systematic review and
Yanping Guo1, Ying Liu1, Ruolin Zhang2
1Department of Pediatrics, Peking University Shenzhen Hospital, Shenzhen, China.
Insights
This systematic review found that amino acids, particularly glutamate, are key metabolites that differ between preterm infants with and without bronchopulmonary dysplasia (BPD). Glutamate may serve as a potential biomarker for early BPD detection.
Area of Science:
- Biochemistry
- Neonatology
- Biomarker Discovery
Background:
- Bronchopulmonary dysplasia (BPD) is a significant complication in preterm infants.
- Early detection of BPD is crucial for timely intervention and improved outcomes.
- Metabolomics offers potential for identifying biomarkers for BPD, but consistent evidence is lacking.
Approach:
- Systematic review and meta-analysis of published metabolomics studies.
- Searched multiple databases (PubMed, Embase, Web of Science, etc.) up to January 2024.
- Included 15 case-control studies with 1357 participants, assessed study quality using Newcastle-Ottawa scale.
Key Points:
- Identified 110 differential metabolites between BPD and non-BPD preterm infants.
- Meta-analysis revealed significantly higher glutamate concentrations in the BPD group (MD=1, 95% CI 0.59 to 1.41, p<0.00001).
- Amino acids emerged as the primary class of distinguishing metabolites.
Conclusions:
- Amino acids, especially glutamate, are key differentiating metabolites in preterm infants with and without BPD.
- Glutamate shows promise as a potential predictive biomarker for BPD in preterm infants.
- Further research is warranted to validate these findings for clinical application.
Abstract:
Numerous studies have attempted to identify potential biomarkers for early detection of bronchopulmonary dysplasia (BPD) in preterm infants using metabolomics techniques. However, the presence of consistent evidence remains elusive. Our study aimed to conduct a systematic review and meta-analysis to identify differences in small-molecule metabolites between BPD and non-BPD preterm infants. Through meticulous screening of numerous samples, we identified promising candidates, providing valuable insights for future research. We searched PubMed, the Cochrane Library, Embase, Web of Science, China National Knowledge Internet, Wan-fang database, Chinese Science and Technique Journal Database and Chinese Biomedical Literature Database from inception until January 16, 2024. Studies were comprehensively reviewed against inclusion criteria. We included case-control studies and adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Study quality was assessed with the Newcastle-Ottawa scale. We compared the changes in metabolite levels between the BPD and non-BPD preterm infants. A meta-analysis was conducted on targeted metabolomics research data based on the strategy of standardized mean differences (MD) and 95% confidence intervals (CI).Fifteen studies (1357 participants) were included. These clinical-based metabolomics studies clarified 110 differential metabolites between BPD and non-BPD preterm infants. The meta-analysis revealed higher glutamate concentration in the BPD group compared to the non-BPD group (MD = 1, 95% CI 0.59 to 1.41, p < 0.00001). Amino acids were identified as the key metabolites distinguishing preterm infants with and without BPD, with glutamate potentially serving as a BPD predictor in this population.
